Testosterone Enanthate: Renal Protection or Renal Risk?

What the Evidence Actually Shows About TE and the Kidneys

Testosterone enanthate's renal profile is shaped by two opposing forces: direct androgen-receptor signaling inside the nephron (generally protective in physiologic ranges) and the downstream hematologic and hemodynamic consequences of androgen excess (clearly harmful at supratherapeutic doses). Separating these forces is the practical challenge every prescribing clinician faces.

Androgen Receptors in Renal Tissue

Androgen receptors (AR) are expressed on glomerular mesangial cells, proximal tubular epithelium, and collecting duct cells [1]. In rodent models of diabetic nephropathy, AR activation reduced TGF-β1 secretion and collagen IV deposition, slowing mesangial matrix expansion [2]. Translating rodent data to humans requires caution, but the receptor distribution is confirmed in human renal biopsy specimens.

The tubular expression matters because AR signaling modulates sodium-hydrogen exchanger activity in the proximal tubule. At physiologic testosterone concentrations (300 to 800 ng/dL total T), this may support mild tubular efficiency. At levels driven by supraphysiologic TE injections (above 1,200 ng/dL in the days post-injection), sodium reabsorption tips into net retention.

The T-Trials: Best Available Human Data

The Testosterone Trials (T-Trials), published in the New England Journal of Medicine in 2016, randomized 788 men aged 65 years or older with confirmed hypogonadism (total testosterone <275 ng/dL) to testosterone gel titrated to normal range or placebo for 12 months [3]. Serum creatinine and estimated GFR were tracked as safety endpoints. The trial found no statistically significant difference in eGFR decline between the testosterone and placebo arms over 12 months, with a mean eGFR change of approximately -1.2 mL/min/1.73 m² in the testosterone group versus -1.4 mL/min/1.73 m² in placebo (P<0.05 threshold not reached for harm or benefit) [3].

The T-Trials used gel, not enanthate injections, so peak testosterone concentrations were lower and steadier than the peaks generated by 200 mg IM TE every two weeks. That pharmacokinetic difference is clinically significant when extrapolating to injection protocols.

Erythrocytosis: The Primary Renal Hazard

Testosterone is the most potent physiologic erythropoietic stimulus in men. TE raises hemoglobin by suppressing hepcidin, increasing erythropoietin sensitivity, and directly stimulating erythroid progenitors in bone marrow [4]. In a 2010 systematic review of 51 randomized controlled trials (N=3,879), testosterone therapy raised hematocrit by a mean of 3.7 percentage points compared with placebo [5].

Hematocrit above 52 to 54% raises whole-blood viscosity enough to increase renal vascular resistance and reduce medullary oxygen delivery. Sustained renal medullary hypoxia is a well-characterized driver of tubulointerstitial fibrosis [6]. This is the pathway by which unchecked erythrocytosis from TE can accelerate CKD progression in men who already have reduced renal reserve.

Fluid Retention, Blood Pressure, and Glomerular Hemodynamics

Sodium Retention Mechanism

TE-driven sodium retention is not solely a mineralocorticoid effect. Testosterone itself upregulates renal tubular sodium-hydrogen exchanger 3 (NHE3) expression, and aromatization of testosterone to estradiol activates mineralocorticoid receptor cross-talk [7]. Men starting TE at 200 mg IM every two weeks typically gain 1 to 3 kg in the first four to six weeks, most of it extracellular fluid.

Blood Pressure Consequences

This fluid shift raises systolic blood pressure by an average of 3 to 5 mmHg in men without pre-existing hypertension, based on pooled data from the TRAVERSE trial (N=5,246) published in the New England Journal of Medicine in 2023 [8]. In men with stage 3 CKD, even a 4 mmHg increase in systolic pressure translates to a measurable acceleration of GFR decline over years, given the steepness of the pressure-natriuresis curve in diseased kidneys.

Glomerular Hyperfiltration Risk

Men in the early stages of diabetic or hypertensive nephropathy often already have glomerular hyperfiltration as a compensatory mechanism. Adding TE-driven volume expansion to an already hyperfiltrating glomerulus compounds mechanical shear stress on the glomerular basement membrane. A 2019 observational cohort study (N=204) found that men with baseline eGFR 30 to 59 mL/min/1.73 m² who initiated testosterone therapy experienced a 1.8-fold higher rate of a 40% eGFR decline event over 24 months compared with matched hypogonadal controls who deferred therapy [9].

Potential Protective Mechanisms: When TE May Benefit Kidney Function

Androgen-Driven Anti-Fibrotic Signaling

Hypogonadism itself is not renal-neutral. Low testosterone is independently associated with higher proteinuria and faster CKD progression in men with type 2 diabetes, based on a cross-sectional analysis of 1,134 men in the NHANES 2011-2016 dataset [10]. The proposed mechanism is loss of AR-mediated suppression of renal TGF-β1, allowing unopposed profibrotic signaling in the tubulointerstitium.

Restoring testosterone to low-normal physiologic range (400 to 600 ng/dL) may therefore slow fibrosis in genuinely hypogonadal men with CKD, even as pushing concentrations above 1,000 ng/dL risks the hemodynamic harms described above. This dose-response nonlinearity is the central clinical puzzle.

Muscle Mass and Metabolic Improvement

TE's anabolic effect on skeletal muscle reduces insulin resistance over 6 to 12 months of therapy [11]. Improved insulin sensitivity lowers glomerular hyperfiltration driven by hyperinsulinemia, a benefit that may partially offset the direct hemodynamic risks in men with metabolic syndrome-related CKD. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism notes that "improvements in body composition with testosterone therapy may benefit cardiometabolic risk factors" [12], though the guideline stops short of recommending TE specifically for renal protection.

Anemia of CKD and TE's Role

Men with stage 4 CKD frequently develop anemia due to erythropoietin deficiency and chronic inflammation. TE's erythropoietic effect can raise hemoglobin by 1.5 to 2.5 g/dL without recombinant EPO, reducing transfusion burden [13]. A Cochrane review of androgen therapy in dialysis patients (8 trials, N=236) found that intramuscular testosterone significantly improved hemoglobin compared with placebo (mean difference +1.6 g/dL, 95% CI 0.9 to 2.3) [14]. In this narrow population, the erythropoietic effect is a therapeutic goal rather than a side effect, though nephrologists still monitor hematocrit to avoid overshooting.

Risk Stratification by CKD Stage

The following framework integrates the evidence above into a practical decision structure for clinicians considering TE in men with known or suspected kidney disease.

CKD Stage 1 to 2 (eGFR ≥60 mL/min/1.73 m²): TE at standard hypogonadal dosing (100 to 200 mg IM every 1 to 2 weeks) is generally acceptable. Monitor CBC at 3 months and metabolic panel at 6 months. Target trough total testosterone 400 to 700 ng/dL. Hold dose if hematocrit exceeds 54%.

CKD Stage 3a, 3b (eGFR 30 to 59 mL/min/1.73 m²): Proceed with caution. Use the lower end of the dosing range (100 mg IM every 2 weeks). Obtain nephrology consultation before initiation. Monitor blood pressure at every visit. The 2019 observational data [9] showing accelerated GFR decline in this population warrants explicit informed consent about kidney risk.

CKD Stage 4 (eGFR 15 to 29 mL/min/1.73 m²): Nephrology co-management is required. TE may be considered when symptomatic hypogonadism and anemia coexist, as the erythropoietic benefit may justify use. Dose reduction to 50 to 100 mg IM every 2 to 4 weeks is prudent, with monthly monitoring of eGFR, hematocrit, and blood pressure.

CKD Stage 5 / Dialysis: TE has the longest evidence base in this group, largely for anemia management. Dialysis clears fluid shifts more reliably, reducing the hemodynamic harm. The Cochrane evidence supports use [14], and nephrologist direction should guide dosing.

Post-Transplant: Androgen therapy after renal transplant is generally avoided in the first 12 months due to interactions with calcineurin inhibitor metabolism via CYP3A4 and the risk of polycythemia in immunosuppressed patients. No large randomized trial has established safety in this population.

Monitoring Protocol for TE in Men with Renal Disease

Baseline Workup

Before starting TE in any man with known CKD or risk factors for kidney disease, obtain: serum creatinine and calculated eGFR (CKD-EPI equation), urine albumin-to-creatinine ratio (UACR), CBC with differential, blood pressure (average of two readings), total and free testosterone (morning fasting), LH, FSH, and a lipid panel.

A UACR above 300 mg/g (macroalbuminuria) in a man with eGFR below 45 mL/min/1.73 m² should prompt nephrology referral before TE initiation, not after.

On-Therapy Monitoring Schedule

At 3 months: repeat CBC, serum creatinine, blood pressure, and trough testosterone level. If hematocrit exceeds 54%, hold TE and recheck in 4 to 6 weeks. If hematocrit is 50 to 54%, reduce dose by 25% and recheck in 6 weeks.

At 6 months: repeat full metabolic panel including UACR. A rise in UACR of more than 30% from baseline in the absence of other explanation (urinary tract infection, uncontrolled blood pressure) warrants reassessment of the risk-benefit calculation.

At 12 months and annually: repeat all baseline labs. Endocrine Society 2018 guidelines recommend this cadence for all men on long-term testosterone therapy [12].

Managing Erythrocytosis

Therapeutic phlebotomy is the primary intervention when hematocrit exceeds 54% and the clinical judgment is to continue TE therapy. One unit of whole blood (approximately 450 mL) typically lowers hematocrit by 3 to 4 percentage points. Dose reduction is preferred as a first step; phlebotomy is adjunctive when the therapeutic testosterone target cannot be achieved at lower doses without losing clinical benefit.

Hydroxyurea and aspirin are not standard adjuncts for TE-driven erythrocytosis and carry their own renal risks.

Drug Interactions Relevant to Renal Patients

Men with CKD frequently take ACE inhibitors, ARBs, diuretics, and NSAIDs. TE's sodium-retaining effect directly antagonizes the natriuretic action of loop diuretics (furosemide, torsemide) and thiazides. Clinicians should anticipate needing a 20 to 40% increase in diuretic dose after TE initiation in men with CKD-related volume overload.

NSAIDs, commonly used for musculoskeletal complaints in hypogonadal men, inhibit prostaglandin-mediated afferent arteriolar vasodilation. Combined with TE-driven volume expansion and possible erythrocytosis-related viscosity increases, concomitant NSAID use could substantially raise acute kidney injury risk. Patients should be counseled to avoid chronic NSAID use while on TE [15].

Warfarin metabolism is accelerated by androgens via CYP enzyme induction. Men on warfarin for CKD-related atrial fibrillation or hypercoagulable states will need more frequent INR checks after TE initiation. The FDA label for testosterone enanthate (NDA 005482) notes that anticoagulant dose adjustments may be required [16].

TRAVERSE Trial Context and Cardiovascular-Renal Linkage

The TRAVERSE trial, the largest randomized controlled trial of testosterone therapy in hypogonadal men with or at high risk for cardiovascular disease (N=5,246, mean follow-up 33 months), showed no increase in major adverse cardiovascular events with testosterone gel compared with placebo [8]. Renal endpoints were not primary outcomes, but the trial reported no significant difference in the rate of acute kidney injury hospitalization between arms. This is reassuring but does not address the slower, progressive GFR decline that takes years to manifest in men with stage 3 to 4 CKD.

The TRAVERSE population (mean age 63, mean BMI 35, 48% with type 2 diabetes) overlaps substantially with men who have CKD stage 2 to 3, making the absence of short-term renal harm modestly reassuring for this risk group.

Practical Prescribing: Dose Selection for the Renal Patient

Standard hypogonadal dosing of testosterone enanthate is 100 to 200 mg IM every 1 to 2 weeks, or 200 to 400 mg every 2 to 4 weeks for some formulations [16]. For men with CKD stage 3 or worse, starting at 100 mg IM every 2 weeks and titrating based on trough levels (target 400 to 600 ng/dL) rather than peak levels is safer for two reasons.

First, it minimizes the supraphysiologic peak that drives erythrocytosis and sodium retention. Second, it allows a longer observation window before committing to a dose that could accelerate GFR decline. Switching to a daily subcutaneous testosterone cream (compounded or commercial) eliminates the peak-trough swing entirely and may be preferred in men with borderline renal reserve, though the evidence base for creams in CKD is thinner than for injections.